¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"particle concentration fluorescence"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • maximum permissible concentration
    ÃÖ´ëÇã¿ë³óµµ
  • mean corpuscular hemoglobin concentration
    Æò±ÕÀûÇ÷±¸Çì¸ð±Û·Îºó³óµµ
  • osmotic concentration
    »ïÅõ³óµµ
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • stress concentration
    ÀÀ·ÂÁýÁß
  • subanesthetic concentration
    ¸¶Ãë´úµÈ³óµµ, ¸¶Ãë¹Ø³óµµ, Áظ¶Ãë³óµµ
  • smoke concentration
    ¸Å¿¬³óµµ
  • urinary solute concentration
    ¿ä¿ëÁú³óµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • molar concentration
    ¸ô³óµµ
  • osmotic concentration
    »ïÅõ³óµµ
  • smoke concentration
    ¸Å¿¬³óµµ
  • stress concentration
    ÀÀ·ÂÁýÁß
  • subanesthetic concentration
    ¸¶Ãë´úµÈ³óµµ, ¸¶Ãë¹Ø³óµµ
  • urinary solute concentration
    ¿ä¿ëÁú³óµµ
  • egg concentration technique
    Áý¶õ¹ý
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • particle immunoassay
    ÀÔÀÚ¸é¿ªÃøÁ¤(¹ý)
  • particle path
    ÀÔÀÚÅë·Î(í£í­÷×ÖØ).
  • particle radiation
    ÀÔÀÚ¼±¹æ»ç¼±Á¶»ç
  • particle weight
    ÀÔÀÚ·®(í£í­åÖ).
  • particle, C-type
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • particle, Danes
    µ¥ÀÎÀÔÀÚ (BÇü °£¿°¹ÙÀÌ·¯½ºÀÇ)
  • particle, viral
    ¹ÙÀÌ·¯½ºÀÔÀÚ
  • particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëºñʾïÁ¦Á¦
  • sigma particle
    ½Ã±×¸¶ÀÔÀÚ
  • viral particle
    ¹ÙÀÌ·¯½ºÀÔÀÚ
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • biological concentration
    ¾à ¸® ¹Ì»ý,±â»ý,¹ÙÀÌ,³»°ú»ý¹°(ÇÐÀû) ³óÃà(¡­ÒØõê).
  • blood alcohol level = blood alcohol concentration
    Ç÷Áß¾ËÄڿóóµµ
  • blood concentration
    Ç÷Áß³óµµ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • kappa particle
    Ä«ÆÄ ÀÔÀÚ(Ø£í­)
  • killer particle
    »ìÀÔÀÚ(߯أí­)
  • messenger ribonucleoprotein particle
    Àü·É(îîÖµ) ¸®º¸ÇÙ»ê(ß«)´Ü¹éÁú ÀÔÀÚ(Ó±ÛÜòõØ£í­)
  • particle diffusion
    ÀÔÀÚÈ®»ê(Ø£í­üªß¤)
  • particle electrophoresis
    ÀÔÀÚ Àü±â¿µµ¿(Ø£í­ï³Ñ¨ç¶ÔÑ)
  • particle immunoassay
    ÀÔÀÚ ¸é¿ª(Ø£í­Øóæ¹)¾Æ½êÀÌ
  • particle scattering factor
    ÀÔÀÚ »ê¶õÀÎÀÚ(Ø£í­ß¤Õ¯ì×í­)
  • particle weight
    ÀÔÀÚ·®(Ø£í­Õá)
  • PM particle
    PM ÀÔÀÚ(Ø£í­)
  • ribosomal particle
    ¶óÀ̺¸¼Ø ÀÔÀÚ(Ø£í­)
  • stripped particle
    ³ªÀÔÀÚ(Ñߨ£í­)
  • subribosomal particle
    ¾Æ(ä¬)¶óÀ̺¸¼Ø ÀÔÀÚ(Ø£í­)
  • transducing particle
    ÇüÁúµµÀÔ ÀÔÀÚ(û¡òõÓôìýØ£í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IAP immunosuppressive acidic protein; inosinic acid pyrophosphorylase; Institute of Animal Physiology; i...
IMP idiopathic myeloid proliferation; impression; incomplete male pseudohermaphroditism; individual Medi...
IPP independent practice plan; individual patient profile; inflatable penile prosthesis; inorganic pyrop...
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
LECP low-energy charged particle
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SPE Solar Particle Event
TSP Total suspended particle
FPF fine particle fraction
CE-LIF Capillary electrophoresis with laser-induced fluorescence detection
EDXRF Energy Dispersive X-Ray Fluorescence
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
proteinaceous infectious particle A proposed pathogen composedonly of protein with no detectable nucleic acid and which is responsible for Creutzfeldt-Jakob disease and kuru inhumans and scrapie in sheep.
(09 Oct 1997)
high energy particle generating unit A machine capable of providing highly energised radiation for the purposes of radiotherapy treatment.
(16 Dec 1997)
signal recognition particle A complex between a 7S RNA and six proteins. SRP binds to the nascent polypeptide chain of eukaryotic proteins with a signal sequence and halts further translation until the ribosome becomes associated with the rough endoplasmic reticulum. One of the SRP proteins (srp54) binds GTP and in association with 7SRNA and srp19 has GTPase activity.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
submitochondrial particle Formed by sonicating mitochondria. Small vesicles in which the inner mitochondrial membrane is inverted to expose the innermost surface.
(18 Nov 1997)
dane particle <virology> 42 nm spherical particle, the complete infective virion of hepatitis B containing a 27 nm core antigen.
(27 Sep 1997)
defective interfering particle An incomplete virus that is unable to replicate and interferes with replication of an infectious virus.
(05 Mar 2000)
D.I. particle <abbreviation> Defective interfering particle.
(05 Mar 2000)
dressed particle <radiobiology> A particle plus its associated neutralising Debye sphere.
(09 Oct 1997)
intramembranous particle <cell biology> Particles (or complementary pits) seen in freeze fractured membranes. The cleavage plane is through the centre of the bilayer and the particles are usually assumed to represent Integral membrane proteins (or polymers of such proteins).
(18 Nov 1997)
either particle flux density The particle fluence rate, or energy flux density, the energy fluence rate of intensity.
Compare: fluence.
(05 Mar 2000)
elementary particle interactions The interactions of particles responsible for their scattering and transformations (decays and reactions). Because of interactions, an isolated particle may decay into other particles. Two particles passing near each other may transform, perhaps into the same particles but with changed momenta (elastic scattering) or into other particles (inelastic scattering). Interactions fall into three groups: strong, electromagnetic, and weak.
(12 Dec 1998)
trapped-particle instability <radiobiology> Slowly-growing class of instabilities driven by particles which cannot circulate freely in a toroidal system.
See: banana orbit.
(09 Oct 1997)
kappa particle <microbiology> Gram-negative bacterial endosymbiont of Paramoecium spp., (Caedobacter taeniospiralis) that confers the killer trait, infected Paramoecium are resistant to the toxin liberated by infected forms. Killing activity is associated with the induction of defective phage in the endosymbiont, leading to the release of R bodies, coded for by the phage genome and apparently of mis assembled phage coat protein.
(18 Nov 1997)
Zimmermann's elementary particle <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels.
Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation.
Synonym: thrombocytes.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á